MX2021011635A - Compuesto para el secuestro de anticuerpos no deseables en un paciente. - Google Patents
Compuesto para el secuestro de anticuerpos no deseables en un paciente.Info
- Publication number
- MX2021011635A MX2021011635A MX2021011635A MX2021011635A MX2021011635A MX 2021011635 A MX2021011635 A MX 2021011635A MX 2021011635 A MX2021011635 A MX 2021011635A MX 2021011635 A MX2021011635 A MX 2021011635A MX 2021011635 A MX2021011635 A MX 2021011635A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- compound
- sub
- sequestration
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona un compuesto para el secuestro de anticuerpos no deseables (por ejemplo, relacionados con una enfermedad autoinmune) en un paciente. El compuesto comprende un andamio de biopolímero inerte y al menos un primer péptido n-mer de la fórmula general P ( - S - P )(n-1) y un segundo péptido n-mer de la fórmula general P ( - S - P )(n-1); en donde, independientemente de cada aparición, P es un péptido con una longitud de secuencia de 2-13 aminoácidos y S es un espaciador no peptídico, en donde, independientemente para cada uno de los péptidos n-mers, n es un número entero de al menos 1, en donde cada uno de los péptidos n-mers está unido al andamio de biopolímero. También se proporcionan composiciones farmacéuticas que comprenden el compuesto, así como un método para secuestrar uno o más anticuerpos presentes en un individuo y un método para inhibir una reacción inmune para un tratamiento con un agente activo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19164784.1A EP3715374A1 (en) | 2019-03-23 | 2019-03-23 | Compound for the sequestration of undesirable antibodies in a patient |
PCT/EP2020/058024 WO2020193486A1 (en) | 2019-03-23 | 2020-03-23 | Compound for the sequestration of undesirable antibodies in a patient |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021011635A true MX2021011635A (es) | 2022-01-04 |
Family
ID=65991526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021011635A MX2021011635A (es) | 2019-03-23 | 2020-03-23 | Compuesto para el secuestro de anticuerpos no deseables en un paciente. |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220062435A1 (es) |
EP (3) | EP3715374A1 (es) |
JP (1) | JP2022528736A (es) |
KR (1) | KR20210142615A (es) |
CN (1) | CN113631581A (es) |
AR (1) | AR121036A1 (es) |
AU (1) | AU2020249341A1 (es) |
BR (1) | BR112021018171A2 (es) |
CA (1) | CA3130187A1 (es) |
DK (1) | DK3898702T3 (es) |
EA (1) | EA202192085A1 (es) |
ES (1) | ES2927642T3 (es) |
IL (1) | IL286589A (es) |
MX (1) | MX2021011635A (es) |
SG (1) | SG11202108756TA (es) |
TW (1) | TW202102520A (es) |
WO (1) | WO2020193486A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11986536B2 (en) * | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
TW202228784A (zh) * | 2020-09-23 | 2022-08-01 | 奧地利商艾柏力維亞生技有限公司 | 用以於一患者中螯合非預期的抗peg抗體的化合物 |
MX2023003377A (es) * | 2020-09-23 | 2023-03-31 | Ablevia Biotech Gmbh | Compuesto para aumentar la eficacia de los vectores virales. |
WO2023180502A1 (en) | 2022-03-24 | 2023-09-28 | Ablevia Biotech Gmbh | Compound for increasing efficacy of oncolytic viruses |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6022544A (en) * | 1983-01-24 | 2000-02-08 | The John Hopkins University | Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry |
US5372933A (en) | 1988-10-03 | 1994-12-13 | The Scripps Research Institute | Polypeptides that mimic receptor-induced binding sites, and methods of using same |
US5268454A (en) * | 1991-02-08 | 1993-12-07 | La Jolla Pharmaceutical Company | Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier |
US6897287B1 (en) | 1990-01-31 | 2005-05-24 | Oklahoma Medical Research Foundation | Ro/SSA peptide reagents for diagnosis of autoantibodies |
US7888458B1 (en) | 1993-11-30 | 2011-02-15 | John B. Harley | Diagnostics and therapy of epstein-barr virus in autoimmune disorders |
EP1135167A2 (en) | 1998-12-09 | 2001-09-26 | La Jolla Pharmaceutical | Methods and formulations for reducing circulating antibodies |
WO2004067549A2 (de) | 2003-01-31 | 2004-08-12 | Max-Delbrück-Centrum für Molekulare Medizin | Peptide gegen kälteunverträglichkeit hervorrufende autoantikörper und ihre verwendung |
US20040258683A1 (en) | 2003-03-30 | 2004-12-23 | Linnik Matthew D. | Methods of treating and monitoring systemic lupus erythematosus in individuals |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
US8210547B2 (en) | 2009-06-16 | 2012-07-03 | Toyota Motor Engineering & Manufacturing North America, Inc. | Active magneto-rheological spring assemblies and vehicle suspension systems incorporating the same |
US20130079280A1 (en) | 2010-04-13 | 2013-03-28 | Medlmmune, Llc | Fibronectin type iii domain-based multimeric scaffolds |
EP2402016A1 (en) | 2010-06-29 | 2012-01-04 | Charité - Universitätsmedizin Berlin | Aptamers that inhibit interaction between antibody and 1st or 2nd extracellular loop of human beta-1-adrenergic receptor |
JP4857396B1 (ja) | 2011-04-13 | 2012-01-18 | 日本製薬株式会社 | 融合蛋白質 |
WO2015056713A1 (ja) | 2013-10-15 | 2015-04-23 | 国立大学法人東京大学 | c-Metタンパク質アゴニスト |
PL3116887T3 (pl) | 2014-03-13 | 2021-09-06 | Universität Basel | Ligandy węglowodanowe, które wiążą się z przeciwciałami igm przeciwko glikoproteinie związanej z mieliną |
WO2015181393A1 (en) * | 2014-05-30 | 2015-12-03 | Per-Johan Jakobsson | Novel sfti and cyclotide based peptides |
EP2982756A1 (en) | 2014-08-04 | 2016-02-10 | Berlin Cures Holding AG | Aptamers for use against autoantibody-associated diseases |
JP6849667B2 (ja) | 2015-09-16 | 2021-03-24 | ウニヴェルズィテート バーゼル | スフィンゴ糖脂質の糖鎖エピトープに対する抗体に結合する炭水化物リガンド |
CA3132021C (en) | 2015-11-18 | 2024-03-12 | Merck Sharp & Dohme Corp. | Pd1 and/or lag3 binders |
ES2858091T3 (es) | 2016-06-20 | 2021-09-29 | F Star Therapeutics Ltd | Moléculas de unión que se unen a PD-L1 y LAG-3 |
CN110799210A (zh) | 2016-12-02 | 2020-02-14 | 得克萨斯A&M大学系统 | 选择性消耗抗原特异性抗体的融合蛋白 |
-
2019
- 2019-03-23 EP EP19164784.1A patent/EP3715374A1/en not_active Ceased
-
2020
- 2020-03-23 EP EP21187621.4A patent/EP3960769A1/en active Pending
- 2020-03-23 CA CA3130187A patent/CA3130187A1/en active Pending
- 2020-03-23 WO PCT/EP2020/058024 patent/WO2020193486A1/en active Search and Examination
- 2020-03-23 ES ES20711964T patent/ES2927642T3/es active Active
- 2020-03-23 SG SG11202108756T patent/SG11202108756TA/en unknown
- 2020-03-23 DK DK20711964.5T patent/DK3898702T3/da active
- 2020-03-23 TW TW109109659A patent/TW202102520A/zh unknown
- 2020-03-23 EA EA202192085A patent/EA202192085A1/ru unknown
- 2020-03-23 EP EP20711964.5A patent/EP3898702B1/en active Active
- 2020-03-23 KR KR1020217028931A patent/KR20210142615A/ko unknown
- 2020-03-23 MX MX2021011635A patent/MX2021011635A/es unknown
- 2020-03-23 JP JP2021560166A patent/JP2022528736A/ja active Pending
- 2020-03-23 CN CN202080023055.8A patent/CN113631581A/zh active Pending
- 2020-03-23 AU AU2020249341A patent/AU2020249341A1/en active Pending
- 2020-03-23 US US17/424,791 patent/US20220062435A1/en active Pending
- 2020-03-23 BR BR112021018171A patent/BR112021018171A2/pt unknown
- 2020-03-25 AR ARP200100819A patent/AR121036A1/es unknown
-
2021
- 2021-09-22 IL IL286589A patent/IL286589A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3898702B1 (en) | 2022-06-29 |
KR20210142615A (ko) | 2021-11-25 |
DK3898702T3 (da) | 2022-09-26 |
EP3960769A1 (en) | 2022-03-02 |
CN113631581A (zh) | 2021-11-09 |
CA3130187A1 (en) | 2020-10-01 |
EP3898702A1 (en) | 2021-10-27 |
WO2020193486A1 (en) | 2020-10-01 |
BR112021018171A2 (pt) | 2021-11-16 |
US20220062435A1 (en) | 2022-03-03 |
JP2022528736A (ja) | 2022-06-15 |
AU2020249341A1 (en) | 2021-11-18 |
TW202102520A (zh) | 2021-01-16 |
AR121036A1 (es) | 2022-04-13 |
IL286589A (en) | 2021-12-01 |
ES2927642T3 (es) | 2022-11-08 |
SG11202108756TA (en) | 2021-10-28 |
EP3715374A1 (en) | 2020-09-30 |
EA202192085A1 (ru) | 2021-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021011635A (es) | Compuesto para el secuestro de anticuerpos no deseables en un paciente. | |
CY1121877T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη | |
ATE254630T1 (de) | Cyclosporine | |
ATE413411T1 (de) | Substituierte cycloalkyl p1' hepatitis c virus inhibitoren | |
HUP0202367A2 (hu) | FAP-aktivált tumorellenes peptidek, eljárás előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
AU2003299519A1 (en) | Hepatitis c virus inhibitors | |
AU2003248535A1 (en) | Heterocyclicsulfonamide hepatitis c virus inhibitors | |
MY140710A (en) | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus | |
EP2423207A3 (en) | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors | |
WO2010068761A3 (en) | 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication | |
ATE154013T1 (de) | Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung | |
BR112013003101A2 (pt) | inibidores do vírus da hepatite c | |
GB2431404A (en) | Peptide | |
ATE383850T1 (de) | Pulver enthaltend neuartige oligosaccharidgemische und verfahren zu deren herstellung | |
WO2009042668A3 (en) | Urea-containing peptides as inhibitors of viral replication | |
NO20072478L (no) | Salter av isofosforamidsennep og analoger av disse som antitumor midler | |
MX2023003377A (es) | Compuesto para aumentar la eficacia de los vectores virales. | |
JP2019534317A5 (es) | ||
RU2015147247A (ru) | Новые соединения, обладающие тройной активностью, тромболизисной, антитромботической и захвата радикалов, и их синтез, наноструктуры и применение | |
EA202192925A1 (ru) | Твердые формы ингибитора glyt1 | |
HUP0401080A2 (hu) | Új görcsoldó sószármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
WO2009095162A8 (en) | Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals | |
RU2009117220A (ru) | Антибактериальные и противовирусные пептиды из actinomadura namibiensis | |
MX2012001200A (es) | (aza)indolizinacarboxamidas ciclicas, su preparacion y su uso como agentes farmaceuticos. | |
BRPI0513741A (pt) | processo de melhoria da imunogeneicidade de um imunogene, antìgeno ou hapteno, complexo imunogênico, ácido nucleico e utilização de um complexo imunogênico |